You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Merck
AstraZeneca
McKinsey
Baxter

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 10,166,244

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,166,244
Title:Targeting NC.sub.CA-ATP channel for organ protection following ischemic episode
Abstract: The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NC.sub.Ca-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.
Inventor(s): Simard; J. Marc (Baltimore, MD)
Assignee: University of Maryland, Baltimore (Baltimore, MD) The United States of America as Represented by the Department of Veteran Affairs (Washington, DC)
Application Number:15/369,056
Patent Claims:see list of patent claims

Details for Patent 10,166,244

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial University of Maryland, Baltimore (Baltimore, MD) The United States of America as Represented by the Department of Veteran Affairs (Washington, DC) 2027-01-12 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Start Trial University of Maryland, Baltimore (Baltimore, MD) The United States of America as Represented by the Department of Veteran Affairs (Washington, DC) 2027-01-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
AstraZeneca
Medtronic
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.